Urine-based detection of Leishmania donovani antibodies using recombinant aurora kinase and otubain cysteine peptidase for noninvasive diagnosis of visceral leishmaniasis
- 1Infectious Diseases and Immunology Division, Council of Scientific and Industrial Research (CSIR)-Indian Institute of Chemical Biology, Kolkata, West Bengal, India
- 2Department of Tropical Medicine, School of Tropical Medicine, Kolkata, West Bengal, India
- 3Department of Molecular Biology, Rajendra Memorial Research Institute of Medical Sciences, Patna, India
Abstract
Visceral leishmaniasis (VL) is a fatal neglected tropical disease that requires early and accurate diagnosis to reduce mortality and interrupt transmission. Although parasitological confirmation using splenic aspirates is the gold standard, it is invasive and hazardous, while blood-based serological tests are often impractical in children and field settings. Consequently, noninvasive urine-based diagnostics represent an important unmet need. In the present study, we investigated the diagnostic utility of two novel Leishmania donovani antigens, otubain cysteine peptidase (LdOCP) and aurora I-related kinase (LdAIRK), using urine samples from VL-endemic regions of India. Both antigens play essential roles in parasite cell cycle progression and survival and are conserved among visceralizing Leishmania species. Urine specimens were collected from 135 individuals aged 10–60 years from Bihar and West Bengal between 2016 and 2024. Following preliminary immunoblot screening, antigen performance was validated using enzyme-linked immunosorbent assay and dipstick formats. Diagnostic accuracy was assessed using rK39 rapid diagnostic test results as the reference standard, and receiver operating characteristic analysis was performed. Both LdOCP and LdAIRK demonstrated 100% sensitivity (95% CI: 93.69–100%) and 100% specificity (95% CI: 86–100%). Mean optical density values were significantly higher in VL patients (0.491 ± 0.266 for LdOCP; 0.749 ± 0.200 for LdAIRK) than in controls (0.092 ± 0.046). Longitudinal analysis revealed a marked decline in antigen-specific antibody levels 6 months after treatment, indicating potential utility as test-of-cure markers. Concordant performance in dipstick assays supports feasibility for urine-based point-of-care diagnosis in resource-limited endemic settings and may aid treatment decisions where laboratory infrastructure is limited.
IMPORTANCE: This study demonstrates that urine-based detection of Leishmania donovani-specific antibodies using LdOCP and LdAIRK provides a highly accurate, noninvasive approach for visceral leishmaniasis diagnosis and prognosis. The excellent sensitivity and specificity, together with a clear post-treatment antibody decline, support application in field and rural settings. Importantly, the proposed urine biomarker panel offers a scalable framework for future development of multiplex, instrument-free diagnostic platforms, facilitating simultaneous detection of multiple pathogens. These findings lay the groundwork for prospective clinical validation, integration into point-of-care workflows, and broader deployment for infectious disease surveillance in resource-limited endemic regions with significant translational public health impact potential.
Related
- PCR Detection and Species Identification of Leishmania in Microscopy-Negative Smears from Suspected Cutaneous Leishmaniasis in Iran
- Development and evaluation of indirect-ELISA based on recombinant nucleoprotein for detection of Ganjam virus (GANV) specific antibodies in small ruminants
- Nano-Based Sodium Stibogluconate for Treatment of Cutaneous Leishmaniasis Caused by Leishmania major in Male Mice.
- Topical Cotton Boll Extract as an Adjunct to Standard Pentavalent Antimonial Therapy in Cutaneous Leishmaniasis Caused by Leishmania tropica: A Randomized Pilot Clinical Trial.
- Nitrile-Based Leishmania Cysteine Protease B Inhibitors with In Vivo Efficacy against Visceral Leishmaniasis
BibTeX
@article{bhattacharyya2026urinebased,
title = {{Urine-based detection of Leishmania donovani antibodies using recombinant aurora kinase and otubain cysteine peptidase for noninvasive diagnosis of visceral leishmaniasis}},
author = {Anirban Bhattacharyya and Mohd Kamran and Rudra Chhajer and Sarfaraz Ahmad Ejazi and Mehebubar Rahman and Rama Prosad Goswami and Major Madhukar and Vidya Nand Ravi Das and Pradeep Das and Krishna Pandey and Nahid Ali},
journal = {Journal of Clinical Microbiology},
year = {2026},
month = sep,
doi = {10.1128/jcm.00409-26},
url = {https://doi.org/10.1128/jcm.00409-26},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Urine-based detection of Leishmania donovani antibodies using recombinant aurora kinase and otubain cysteine peptidase for noninvasive diagnosis of visceral leishmaniasis
AU - Anirban Bhattacharyya
AU - Mohd Kamran
AU - Rudra Chhajer
AU - Sarfaraz Ahmad Ejazi
AU - Mehebubar Rahman
AU - Rama Prosad Goswami
AU - Major Madhukar
AU - Vidya Nand Ravi Das
AU - Pradeep Das
AU - Krishna Pandey
AU - Nahid Ali
PY - 2026
DA - 2026/09/25
JO - Journal of Clinical Microbiology
DO - 10.1128/jcm.00409-26
UR - https://doi.org/10.1128/jcm.00409-26
AB - Visceral leishmaniasis (VL) is a fatal neglected tropical disease that requires early and accurate diagnosis to reduce mortality and interrupt transmission. Although parasitological confirmation using splenic aspirates is the gold standard, it is invasive and hazardous, while blood-based serological tests are often impractical in children and field settings. Consequently, noninvasive urine-based diagnostics represent an important unmet need. In the present study, we investigated the diagnostic utility of two novel Leishmania donovani antigens, otubain cysteine peptidase (LdOCP) and aurora I-related kinase (LdAIRK), using urine samples from VL-endemic regions of India. Both antigens play essential roles in parasite cell cycle progression and survival and are conserved among visceralizing Leishmania species. Urine specimens were collected from 135 individuals aged 10–60 years from Bihar and West Bengal between 2016 and 2024. Following preliminary immunoblot screening, antigen performance was validated using enzyme-linked immunosorbent assay and dipstick formats. Diagnostic accuracy was assessed using rK39 rapid diagnostic test results as the reference standard, and receiver operating characteristic analysis was performed. Both LdOCP and LdAIRK demonstrated 100% sensitivity (95% CI: 93.69–100%) and 100% specificity (95% CI: 86–100%). Mean optical density values were significantly higher in VL patients (0.491 ± 0.266 for LdOCP; 0.749 ± 0.200 for LdAIRK) than in controls (0.092 ± 0.046). Longitudinal analysis revealed a marked decline in antigen-specific antibody levels 6 months after treatment, indicating potential utility as test-of-cure markers. Concordant performance in dipstick assays supports feasibility for urine-based point-of-care diagnosis in resource-limited endemic settings and may aid treatment decisions where laboratory infrastructure is limited. IMPORTANCE: This study demonstrates that urine-based detection of Leishmania donovani-specific antibodies using LdOCP and LdAIRK provides a highly accurate, noninvasive approach for visceral leishmaniasis diagnosis and prognosis. The excellent sensitivity and specificity, together with a clear post-treatment antibody decline, support application in field and rural settings. Importantly, the proposed urine biomarker panel offers a scalable framework for future development of multiplex, instrument-free diagnostic platforms, facilitating simultaneous detection of multiple pathogens. These findings lay the groundwork for prospective clinical validation, integration into point-of-care workflows, and broader deployment for infectious disease surveillance in resource-limited endemic regions with significant translational public health impact potential.
SN - 0095-1137
SN - 1098-660X
ER -